{
    "clinical_study": {
        "@rank": "94045", 
        "acronym": "PIPAC-GA01", 
        "arm_group": {
            "arm_group_label": "Intraperitoneal Chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks."
        }, 
        "brief_summary": {
            "textblock": "A prospective series of patients with recurrent gastric cancer will be treated with three\n      cycles of chemotherapy (doxorubicin and cisplatin) instilled into the abdominal cavity in\n      the form of an aerosol under pressure via laparoscopy. The efficacy of this treatment will\n      be assessed by computed tomography, tumor marker studies, and survival. Also, the safety of\n      the procedure will be assessed."
        }, 
        "brief_title": "Intraperitoneal Aerosol Chemotherapy in Gastric Cancer", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Objectives: To evaluate the safety and efficacy in terms of the clinical benefit rate (CBR)\n      of PIPAC in peritoneal carcinomatosis (PC) from gastric cancer (GC) Study design: Single\n      center, open label, non-randomized, single-arm, repeated single dose study to explore the\n      efficacy, safety, and CBR of doxorubicin and cisplatin when given as a pressurized\n      intraperitoneal aerosol chemotherapy (PIPAC) to patients with advanced gastric cancer and\n      peritoneal carcinomatosis.\n\n      Target subject population:Patients with GC and PC with disease progression after at least\n      one line of previous i.v. chemotherapy.\n\n      Investigational product, dosage and mode of administration Doxorubicin 1.5 mg/m2 body\n      surface in 50 ml NaCl 0,9% and Cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied\n      intraperitoneally as PIPAC.\n\n      Duration of treatment: 3 single doses in 6 weeks intervals, duration of treatment is 18\n      weeks\n\n      Outcome variables:\n\n      1.1 Primary outcome variable \u2022 Clinical Benefit Rate (CBR) according to Response Evaluation\n      Criteria In Solid Tumors (RECIST) criteria (version 1.1) after 3 cycles of PIPAC with\n      cisplatin and doxorubicin.\n\n      1.2 Secondary outcome variables\n\n        -  The observed survival (OS)\n\n        -  The median time to progression (TTP) according to RECIST criteria after three cycles of\n           PIPAC with cisplatin and doxorubicin\n\n        -  The Peritoneal Carcinomatosis Index (PCI) before and after therapy\n\n        -  The degree of histological regression assessed by pathological review\n\n        -  Apoptosis as assessed by immunohistochemical analysis\n\n        -  The difference in ascites volume before and after the first, second, and third PIPAC\n           application 1.3 Patient reported outcomes (PROs)\n\n        -  European Organization for Research and Treatment of Cancer (EORTC) quality of life\n           questionnaire (QLQ-C30, German version ) 1.4 Safety\n\n        -  Safety and tolerability will be assessed by collection of adverse events, according to\n           the Common Terminology Criteria for Adverse Events (CTCAE)   including physical\n           examination results, laboratory assessments (chemistry and hematology).\n\n      1.5 Biological monitoring\n\n      \u2022 Basic research investigating expression of genes associated with drug resistance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age above 18 years\n\n          -  written, informed consent\n\n          -  presence of peritoneal carcinomatosis\n\n        Exclusion Criteria:\n\n          -  language barrier\n\n          -  parenchymal metastases\n\n          -  unability to undergo laparoscopy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854255", 
            "org_study_id": "PIPAC-GA01"
        }, 
        "intervention": {
            "arm_group_label": "Intraperitoneal Chemotherapy", 
            "description": "doxorubicin and cisplatin as intraperitoneal chemotherapy", 
            "intervention_name": "doxorubicin and cisplatin", 
            "intervention_type": "Drug", 
            "other_name": [
                "doxorubicin 50 HEXAL\u00ae", 
                "cisplatin 10 HEXAL\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Doxorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastric", 
            "Cancer", 
            "Chemotherapy", 
            "Intraperitoneal"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "location": {
            "contact": {
                "email": "marc.reymond@marienhospital-herne.de", 
                "last_name": "Marc A Reymond, MD", 
                "phone": "02323 499", 
                "phone_ext": "1478"
            }, 
            "facility": {
                "address": {
                    "city": "Herne", 
                    "country": "Germany", 
                    "state": "North Rhine Westphalia", 
                    "zip": "44625"
                }, 
                "name": "Ruhr University of Bochum"
            }, 
            "investigator": {
                "last_name": "Marc A Reymond, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Patients With Gastric Cancer and Peritoneal Carcinomatosis: an Open-label, Single-arm, Phase II Clinical Trial", 
        "other_outcome": {
            "description": "Time to progression according to RECIST criteria during treatment and during follow-up of 1 year", 
            "measure": "median time ot progression", 
            "safety_issue": "No", 
            "time_frame": "during treatment and follow-up of 1 year"
        }, 
        "overall_contact": {
            "email": "marc.reymond@marienhospital-herne.de", 
            "last_name": "Marc A Reymond, MD", 
            "phone": "02323 499", 
            "phone_ext": "1478"
        }, 
        "overall_official": {
            "affiliation": "Ruhr University of Bochum", 
            "last_name": "Marc A Reymond, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical Benefit Rate according to RECIST criteria after 3 cycles of PIPAC with cisplatin and doxorubicin.", 
            "measure": "Clinical Benefit Rate", 
            "safety_issue": "No", 
            "time_frame": "within 3 months after treatment completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854255"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ruhr University of Bochum", 
            "investigator_full_name": "Clemens Tempfer", 
            "investigator_title": "Clemens Tempfer, MD, MBA", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Survival will be assessed by direct observation during treatment and by follow-up investigation for 1 year after completion of the study", 
            "measure": "Observed Survival", 
            "safety_issue": "No", 
            "time_frame": "During treatment and follow-up of 1 year"
        }, 
        "source": "Ruhr University of Bochum", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ruhr University of Bochum", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}